Journal
SCHIZOPHRENIA RESEARCH
Volume 72, Issue 1, Pages 21-28Publisher
ELSEVIER
DOI: 10.1016/j.schres.2004.09.008
Keywords
cognition; neuropsychology; psychopharmacology; schizophrenia; course
Categories
Ask authors/readers for more resources
Cognitive impairment has emerged as an important new target in schizophrenia therapeutics in light of evidence that cognitive deficits are critically related to the functional of disability that is characteristic of the illness. Evidence is briefly reviewed supporting the idea that the cognitive impairment in schizophrenia is an attractive target for therapeutic intervention including: (1) there is a characteristic pattern of cognitive deficits that occur with very high frequency; (2) the deficits are relatively stable over time; and (3) cognitive deficits are relatively independent of the symptomatic manifestations of the illness. Thus, cognitive impairment appears to be a well-defined, reliable and distinct dimension of the illness. (C) 2004 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available